Metabolic & GLP-1

1. Metabolic & GLP-1well supported · human dataAdded 18 August 2026

   Exercise cools chronic inflammation, but only if your fitness actually improves

   Across 106 trials in 8,642 adults with overweight or obesity, long-term exercise of any structured mode lowered circulating inflammatory markers including CRP, IL-6, TNF-α and leptin. The benefit tracked with improvements in VO2max, and spontaneous physical activity alone was not effective.

   ⚠What it shows: A strong signal: results pooled from 106 trials in 8,642 adults with overweight or obesity, though the trials varied widely in design and length. The fitness link comes from statistical analysis across studies rather than a direct head-to-head test.Meta-analysis · Obes Rev

   Full breakdown →VO₂max explained →VO2max Calculator →Long-term effects of different exercise training modes on cytokines and adipokines in individuals with overweight/obesity and cardiometabolic diseases: A systematic review, meta-analysis, and meta-regression of randomized controlled trials. Obes Rev 2023
2. Metabolic & GLP-1preliminary · human dataAdded 18 August 2026

   In type 2 diabetes, exercise tames inflammation but leaves cholesterol untouched

   A meta-analysis of 25 trials in 1257 people with type 2 diabetes found exercise training raised adiponectin and lowered inflammatory markers, fasting insulin and insulin resistance, yet lipid profiles did not improve.

   ⚠What it shows: Encouraging but not final: results pooled from 25 trials in 1257 people with type 2 diabetes pointed the same way, but the studies disagreed with each other considerably and the authors want more trials before calling it settled.Meta-analysis · Biol Res Nurs

   Full breakdown →Insulin sensitivity explained →Effects of Exercise Training on Inflammatory and Cardiometabolic Risk Biomarkers in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Biol Res Nurs 2023
3. Metabolic & GLP-1well supported · human dataAdded 18 August 2026

   Tirzepatide beats the original weight-loss jabs, not just placebo

   Pooled results from six randomised trials in 6266 adults with overweight or obesity found once-weekly tirzepatide beat both placebo and GLP-1 drugs for weight loss at every dose tested, with high-certainty evidence for achieving at least 15% weight loss. Gut side effects matched the GLP-1 drugs but were significantly more common than with placebo.

   ⚠What it shows: About as solid as weight-loss drug evidence gets: results pooled from six trials covering 6266 adults, rated high certainty for reaching at least 15% weight loss. The open questions are how much lean tissue goes with the fat and how well people tolerate the gut side effects long term.Meta-analysis · J Obes

   Full breakdown →Energy balance explained →Calorie Deficit Calculator →Weight Loss Efficacy of Tirzepatide Compared to Placebo or GLP-1 Receptor Agonists in Adults With Obesity or Overweight: A Meta-Analysis of Randomized Controlled Trials With ≥ 20 Weeks Treatment Duration. J Obes 2025
4. Metabolic & GLP-1well supported · human dataAdded 17 August 2026

   Blood sugar falls further once exercise tops 150 minutes a week

   In adults with type 2 diabetes, structured exercise training was associated with a 0.67% drop in HbA1c versus control, and programmes over 150 minutes per week were linked to a 0.89% reduction against 0.36% for shorter ones. Advice to be active was only associated with lower HbA1c when paired with dietary advice.

   ⚠What it shows: Strong by weight of numbers: results pooled from 47 trials with 8538 people with type 2 diabetes, all lasting at least 12 weeks. The trials varied a great deal in design and populations, so the percentage drops are averages across very different programmes rather than a guarantee for any one person.Meta-analysis · JAMA

   Full breakdown →Insulin sensitivity explained →Metabolic Fitness Index →Physical activity advice only or structured exercise training and association with HbA1c levels in type 2 diabetes: a systematic review and meta-analysis. JAMA 2011
5. Metabolic & GLP-1well supported · human dataAdded 17 August 2026

   Tirzepatide beats older GLP-1 drugs for weight loss, at a gut-side-effect cost

   In a pooled analysis of 12 randomised trials with 11,758 participants, tirzepatide reduced body weight, BMI and waist circumference more than GLP-1 receptor agonists, placebo or insulin, though gastrointestinal side effects were more common.

   ⚠What it shows: Strong pooled evidence: 12 trials with 11,758 people, all assigned at random, and the results pointed the same way against every comparator. The clear trade-off is tolerability, with nausea and other gut side effects markedly more common than placebo.Meta-analysis · Front Public Health

   Full breakdown →Energy balance explained →Calorie Deficit Calculator →Tirzepatide as a novel effective and safe strategy for treating obesity: a systematic review and meta-analysis of randomized controlled trials. Front Public Health 2024
6. Metabolic & GLP-1well supported · human dataAdded 17 August 2026

   GLP-1 drugs show no overall cancer risk across 50 trials, with one thyroid caveat

   Across 50 randomised trials lasting at least a year, GLP-1 receptor agonists were not linked to any overall increase in cancer risk; a signal for higher thyroid cancer risk, and a possible reduction in uterine cancer in obesity trials, both warrant further study.

   ⚠What it shows: Broadly reassuring: results pooled from 50 drug trials that each ran for at least a year found no overall cancer difference. The thyroid signal deserves dedicated study rather than alarm, and several authors report fees from the companies that make these drugs.Meta-analysis · Diabetes Obes Metab

   Full breakdown →GLP-1 explained →Healthy Lifestyle & Life Expectancy →GLP-1 receptor agonists and the risk for cancer: A meta-analysis of randomized controlled trials. Diabetes Obes Metab 2025
7. Metabolic & GLP-1well supported · human dataAdded 17 August 2026

   Fasted workouts show no metabolic edge over fed ones

   Across 28 trials in 302 healthy adults, single fasted workouts were associated with larger rises in glucose and insulin and larger drops in free fatty acids than fed workouts, with no difference in triglycerides or the body's fuel-use ratio. The pooled results give no support to the idea that fasted sessions are better for glucose or fat metabolism.

   ⚠What it shows: Worth taking seriously but deliberately narrow: results pooled from 28 trials in 302 healthy adults, all measuring single workouts lasting 36 to 150 minutes. It says nothing about whether weeks of habitual fasted training change fat loss, fitness or long-term metabolic health.Meta-analysis · Clin Nutr ESPEN

   Full breakdown →Insulin sensitivity explained →The effects of acute bouts of exercise in fasted vs. fed states on glucose and lipid metabolism in healthy adults: A systematic review and meta-analysis of randomized clinical trials. Clin Nutr ESPEN 2025
8. Metabolic & GLP-1well supported · human dataAdded 17 August 2026

   Steady cardio for the scales, HIIT for the waist

   In a pooled comparison of 28 randomised trials in 1,620 adults with overweight or obesity, aerobic exercise ranked best for reducing body weight and BMI, while HIIT ranked best for waist circumference, body fat, triglycerides, fasting glucose and VO2 max. No training mode significantly improved total cholesterol or blood pressure.

   ⚠What it shows: A useful ranking rather than a final verdict: results pooled from 28 trials in 1,620 adults with overweight or obesity, comparing four training styles side by side. Rankings like this lean partly on indirect comparisons between trials that never faced each other, so the gaps between modes are less certain than they look.Meta-analysis · Front Endocrinol (Lausanne)

   Full breakdown →HIIT explained →Heart Rate Zone Calculator →Comparative efficacy of exercise training modes on systemic metabolic health in adults with overweight and obesity: a network meta-analysis of randomized controlled trials. Front Endocrinol (Lausanne) 2023
9. Metabolic & GLP-1well supported · human dataAdded 16 August 2026

   Tirzepatide lowers blood pressure so much it can go too low

   Pooled results from 32 randomised trials covering 47,332 people with type 2 diabetes or obesity linked tirzepatide to a 60% lower risk of hypertension-related adverse events but roughly two and a half times the risk of hypotension-related events, especially at higher doses. Semaglutide showed no significant link with blood pressure events in either direction.

   ⚠What it shows: Strong pooled evidence: 32 trials where people were assigned at random, covering 47,332 people with type 2 diabetes or obesity. The catch is that these were side effects logged during drug trials built for other questions, not studies designed to measure blood pressure itself.Meta-analysis · Endocrine

   Full breakdown →Metabolic syndrome explained →Heart Age Calculator →Effect of tirzepatide and semaglutide on blood pressure: A systematic review and meta-analysis. Endocrine 2026
10. Metabolic & GLP-1well supported · human dataAdded 16 August 2026

    Semaglutide loses the weight loss crown to retatrutide

    In a pooled comparison of 27 randomised trials covering 15,584 people with obesity or overweight, retatrutide 12 mg cut body weight by 22.10% versus placebo, ahead of retatrutide 8 mg at 20.70% and tirzepatide 15 mg at 16.53%, making multi-hormone agonists more effective than single GLP-1 drugs including semaglutide.

    ⚠What it shows: About as strong as it gets short of direct head-to-head trials: results pooled from 27 trials of 15,584 people, though most drugs were compared through a shared placebo rather than against each other directly. People with type 2 diabetes lost noticeably less weight on the same drugs.Meta-analysis · Metabolism

    Full breakdown →GLP-1 explained →Seven glucagon-like peptide-1 receptor agonists and polyagonists for weight loss in patients with obesity or overweight: an updated systematic review and network meta-analysis of randomized controlled trials. Metabolism 2024
11. Metabolic & GLP-1preliminary · human dataAdded 15 August 2026

    Cardio moved every marker of metabolic syndrome in older adults with diabetes

    Pooled results from 7 randomised trials found aerobic exercise improved fasting glucose, systolic and diastolic blood pressure, HbA1c, HDL cholesterol and triglycerides in older adults with type 2 diabetes, with no significant adverse effects reported.

    ⚠What it shows: Encouraging but thin: results pooled from just 7 trials, and the certainty was rated moderate for blood pressure, low for glucose and very low for everything else. The trials tracked lab markers rather than symptoms or complications, so the real-world payoff is not yet proven.Meta-analysis · Rev Peru Med Exp Salud Publica

    Full breakdown →Metabolic syndrome explained →Heart Rate Zone Calculator →Effects of aerobic exercise on components of the metabolic syndrome in older adults with type 2 diabetes mellitus: systematic review and meta-analysis. Rev Peru Med Exp Salud Publica 2024
12. Metabolic & GLP-1preliminary · human dataAdded 15 August 2026

    GLP-1 jabs show no link to pancreatitis or pancreatic cancer

    Pooled data from 52 studies found no association between GLP-1 receptor agonists used for weight loss in obesity and an increased risk of pancreatitis or pancreatic cancer, with findings consistent across drug type, dose, study design and follow-up duration.

    ⚠What it shows: About as reassuring as pooled evidence gets: 52 studies in people with obesity, and the null result held across drug type, dose, study design and follow-up length. The estimate for pancreatic cancer still carried a wide band of uncertainty, so a modest effect cannot be completely ruled out.Study · Horm Metab Res

    Full breakdown →GLP-1 explained →Calorie Deficit Calculator →Effects of Glucagon-Like Peptide-1 Receptor Agonists as Weight Loss Drugs on Pancreatitis and Pancreatic Cancer: A Meta-Analysis. Horm Metab Res 2026
13. Metabolic & GLP-1well supported · human dataAdded 15 August 2026

    GLP-1 drugs shave an average 4.57 kg, and the youngest lose most

    GLP-1 receptor agonist drugs cut body weight by an average of 4.57 kg and trimmed 4.55 cm off the waist compared with placebo, across a pooled analysis of 47 randomised trials in adults with overweight or obesity.

    ⚠What it shows: Strong evidence: results pooled from 47 trials in 23,244 adults with overweight or obesity. The trials varied widely in drugs, doses and populations, so the averages hide big differences from one drug and one person to the next.Meta-analysis · Diabetes Care

    Full breakdown →Visceral fat explained →Calorie Deficit Calculator →Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference for Patients With Obesity or Overweight: A Systematic Review, Meta-analysis, and Meta-regression of 47 Randomized Controlled Trials. Diabetes Care 2025
14. Metabolic & GLP-1well supported · human dataAdded 15 August 2026

    The next weight-loss drug may beat them all: retatrutide hit 22.1%

    In adults with overweight or obesity but no diabetes, tirzepatide produced up to 17.8% weight loss, semaglutide up to 13.9%, and the premarket drug retatrutide up to 22.1% across a review of 26 randomised trials. Side effects were common but mostly gastrointestinal, and rarely forced people to stop treatment.

    ⚠What it shows: A thorough sweep of 26 placebo-controlled trials in 15,491 people without diabetes, but the trials differed too much to pool into one number. None compared the drugs head to head, so the league table rests on separate trials in different populations.Systematic review · Ann Intern Med

    Full breakdown →Energy balance explained →Calorie Deficit Calculator →Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss Among Adults Without Diabetes : A Systematic Review of Randomized Controlled Trials. Ann Intern Med 2025
15. Metabolic & GLP-1preliminary · human dataAdded 14 August 2026

    One day of glucose data can flag hidden diabetes risk

    A single day of continuous glucose monitor data may reveal hidden diabetes risk in people with prediabetes: those with a High Blood Glucose Index above 0.174 had a 5.39- to 6.13-fold higher risk of progressing to type 2 diabetes, even when their standard glucose readings sat within recommended ranges. The metric behaved consistently across three different monitor brands.

    ⚠What it shows: Promising but early: the finding comes from 365 glucose monitor records across four separate groups of people, and so few actually progressed to diabetes that the 0.174 cut-off still needs confirming in bigger, independent groups before anyone acts on it.Study · Diabet Med

    Full breakdown →Insulin sensitivity explained →Metabolic Fitness Index →High blood glucose index stratifies glycaemic severity and identifies occult type 2 diabetes risk in prediabetes via single-day continuous glucose monitoring: A multi-cohort study. Diabet Med 2026
16. Metabolic & GLP-1well supported · human dataAdded 14 August 2026

    Cardio's blood sugar benefit plateaus at 100 minutes a week

    In adults with type 2 diabetes, every 30 minutes per week of supervised aerobic exercise cut HbA1c by 0.22 percentage points, with the benefit climbing to a 0.96 point drop at 100 minutes per week. Beyond 100 minutes the curve flattened, so extra weekly cardio bought no further HbA1c reduction.

    ⚠What it shows: About as strong as exercise evidence gets for the headline effect, which the authors rated high certainty: results pooled from 26 trials in 1253 adults with type 2 diabetes. The medication and side-effect numbers rest on far fewer trials and are much softer.Meta-analysis · Sports Med

    Full breakdown →Insulin sensitivity explained →Metabolic Fitness Index →Dose-Dependent Effect of Supervised Aerobic Exercise on HbA(1c) in Patients with Type 2 Diabetes: A Meta-analysis of Randomized Controlled Trials. Sports Med 2022
17. Metabolic & GLP-1preliminary · human dataAdded 14 August 2026

    Two routine blood tests flag atrial fibrillation risk

    Across 19 pooled studies following 25,376 people, mostly in Asia, each 1-unit rise in the triglyceride-glucose (TyG) index, a low-cost blood marker of insulin resistance, was associated with a 114% higher risk of atrial fibrillation.

    ⚠What it shows: Treat this as a strong signal rather than a verdict: results pooled from 19 studies that followed 25,376 people rather than testing anything on them, so it cannot prove the marker causes the rhythm problem. Nearly all the data come from Asian populations and the studies disagreed on the size of the link, so the exact figures travel with caution.Review · Front Cardiovasc Med

    Full breakdown →Insulin sensitivity explained →Metabolic Fitness Index →Triglyceride-glucose index and atrial fibrillation: a systematic review and meta-analysis. Front Cardiovasc Med 2026
18. Metabolic & GLP-1preliminary · human dataAdded 13 August 2026

    No detectable rise in depression risk on semaglutide, pooled data suggest

    Pooled evidence finds no statistically significant increase in depression, anxiety or suicidal thoughts among people taking semaglutide compared with placebo or other treatments. The authors stress this is an absence of detected risk in noisy data, not definitive proof of safety.

    ⚠What it shows: Reassuring rather than final: the pooled sources, from proper trials to voluntary side-effect reports, disagreed with each other sharply and some carried real risk of bias. That messiness means a modest effect in either direction cannot be ruled out.Meta-analysis · Clin Obes

    Full breakdown →GLP-1 explained →Burden and Risk of Depression in Patients Receiving Semaglutide: A Systematic Review and Meta-Analysis. Clin Obes 2026
19. Metabolic & GLP-1preliminary · human dataAdded 13 August 2026

    The next weight-loss jab targets amylin, a different hormone entirely

    In pooled data from four trials of 5425 adults with overweight or obesity, weekly cagrilintide cut body weight by 6.08% versus placebo, and the CagriSema combination with semaglutide cut it by 5.98% while also trimming waist size by 10.91 cm and improving blood sugar. Both treatments modestly increased adverse events.

    ⚠What it shows: Promising but young: just four trials with 5425 people in total, and their results varied a lot from one to the next. Longer studies are still needed before anyone knows how safe and durable these drugs are.Study · Ann Med Surg (Lond)

    Full breakdown →Calorie Deficit Calculator →Amylin-based obesity therapy: a meta-analysis of Cagrilintide and CagriSema versus placebo. Ann Med Surg (Lond) 2026
20. Metabolic & GLP-1preliminary · human dataAdded 13 August 2026

    Heartburn pills may quietly lower blood sugar

    Acid-reflux drugs may double as mild glucose lowerers: across 15 studies of 2,038 people, proton pump inhibitor use was linked with a 5.32 mg/dL fall in fasting blood glucose, with the biggest apparent benefit in poorly controlled type 2 diabetes. HbA1c results were inconsistent and insulin resistance did not change.

    ⚠What it shows: Intriguing but shaky: 15 mostly small studies totalling 2,038 people, mixing proper trials with weaker designs, and the review itself was never registered in advance. Treat the exact size of the glucose drop loosely.Review · J Midlife Health

    Full breakdown →Insulin sensitivity explained →Metabolic Fitness Index →Impact of Proton Pump Inhibitors on Blood Glucose in Type 2 Diabetes: A Systematic Review with Meta-analysis. J Midlife Health 2026
21. Metabolic & GLP-1well supported · human dataAdded 13 August 2026

    Soluble fibre nudges every cholesterol number the right way in type 2 diabetes

    Pooled results from 38 randomised trials suggest soluble fibre supplements improved every standard blood fat measure in people with type 2 diabetes: triglycerides fell by 16.97 mg/dL, LDL cholesterol by 11.14 mg/dL, total cholesterol by 13.87 mg/dL, and HDL cholesterol rose by 1.74 mg/dL.

    ⚠What it shows: Strong as supplement evidence goes: results pooled from 38 trials, all in people with type 2 diabetes, and all four blood fat measures moved the same way. The improvements are modest, and it is not yet known whether they translate into fewer heart problems.Meta-analysis · Prostaglandins Other Lipid Mediat

    Full breakdown →ApoB explained →Heart Age Calculator →Effect of soluble fiber supplementation on lipid parameters in subjects with type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials. Prostaglandins Other Lipid Mediat 2025
22. Metabolic & GLP-1well supported · human dataAdded 13 August 2026

    For blood sugar and cholesterol, lifting alone loses to cardio

    Endurance training and combined endurance-strength training improved blood sugar control and cholesterol more than strength training alone in overweight and obese adults, in a meta-analysis of 46 trials. Combined training also beat endurance alone on insulin resistance and triglycerides.

    ⚠What it shows: Solid but not settled: results pooled from 46 trials in overweight and obese adults, but the trials disagreed with each other quite a bit, so the exact size of each advantage is uncertain even if the overall direction looks consistent.Meta-analysis · Int J Environ Res Public Health

    Full breakdown →Insulin sensitivity explained →Metabolic Fitness Index →Comparison of the Effect of Endurance, Strength and Endurance-Strength Training on Glucose and Insulin Homeostasis and the Lipid Profile of Overweight and Obese Subjects: A Systematic Review and Meta-Analysis. Int J Environ Res Public Health 2022
23. Metabolic & GLP-1well supported · human dataAdded 13 August 2026

    Aerobic exercise moves nearly every metabolic dial in type 2 diabetes

    Across 34 randomised trials covering 1391 adults with type 2 diabetes plus overweight or obesity, aerobic exercise improved blood glucose, glycated haemoglobin, insulin resistance, body fat, waist size and cholesterol compared with standard treatment alone.

    ⚠What it shows: Strong direction, fuzzy sizes: results pooled from 34 trials in 1391 middle-aged and older adults with type 2 diabetes and excess weight, and most improvements were modest. The authors themselves flag considerable uncertainty in several of the outcomes.Meta-analysis · J Diabetes Complications

    Full breakdown →Insulin sensitivity explained →Metabolic Fitness Index →Impact of aerobic exercise on cardiometabolic health in patients with diabesity: A systematic review and meta-analysis of randomized controlled trials. J Diabetes Complications 2025
24. Metabolic & GLP-1well supported · human dataAdded 12 August 2026

    Garlic nudges cholesterol, blood pressure and waistlines the right way

    Garlic supplementation reduced triglycerides, total cholesterol, LDL cholesterol, diastolic blood pressure, BMI and waist circumference versus placebo across 19 randomised trials of 999 adults with metabolic disorders.

    ⚠What it shows: Worth noting, not a prescription: results pooled from 19 trials of 999 adults with metabolic problems favoured garlic across six risk markers, but the studies disagreed with each other considerably. There are also signs that trials with negative results may never have been published, which would flatter the picture.Meta-analysis · BMC Complement Med Ther

    Full breakdown →Metabolic syndrome explained →Metabolic Fitness Index →Effects of garlic supplementation on components of metabolic syndrome: a systematic review, meta-analysis, and meta-regression of randomized controlled trials. BMC Complement Med Ther 2023

Back to the full archive · this week’s studies